Although most skin problems are harmless, a minor one can become serious in people who have diabetes. Whether it’s the common skin tag or more tongue-twisting things like necrobiosis lipoidica, you should be aware of the dermatologic conditions that could be precursors or signs of diabetes in your patients. With images and descriptions, this resource will provide a great review of the conditions.

The data was presented to the FDA, which reported 789 cases of myocarditis/pericarditis – predominantly in males – after receiving the Pfizer/BioNTech and Moderna vaccines, most commonly after the second dose. Symptoms included chest pain, elevated cardiac enzymes, ST or T wave changes, dyspnea, and abnormal echocardiography/imaging for those ages 30 years and younger.

Both men and women can be affected by medications that cause unwanted side effects, one of which can be sexual dysfunction. It’s important to talk to your patients about how to manage their primary conditions while working with them to alleviate the problems associated with these common medications that affect sex drive.

There have been few studies that have used validated measures to investigate the sexual harassment of physicians, never mind the sexual harassment of oncologists. According to the authors, this report is the first of its kind to examine the prevalence and types of sexual harassment experienced by oncologists, measuring their work experiences in three forms: sexual attention, sexual coercion, and gender harassment.

Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose interferon.

The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab and LAG-3 target relatlimab holds the cancer in check significantly longer than nivolumab alone.